Literature DB >> 2544985

Expression of activation markers on CD4+ and CD8+ cells from synovial fluid, synovial tissue, and peripheral blood of patients with inflammatory arthritides.

J Hovdenes1, G Gaudernack, T K Kvien, T Egeland.   

Abstract

We studied the expression of the Tac antigen, the transferrin receptor (Tfr-R), HLA class II antigens (DR, DQ, DP), CD30, and Act 1 on purified CD4+ and CD8+ cells isolated from synovial fluid (SF), synovial tissue (ST), and peripheral blood (PB) of patients with rheumatoid arthritis (RA) and with non-RA inflammatory arthritides (not ST). Subfractionated T cells of PB from healthy individuals served as controls. SF CD4+ cells from RA and non-RA arthritides expressed the Tac antigen much more frequently than corresponding CD8+ cells (54 and 58% versus 16 and 17%). In contrast, SF CD8+ cells of both patient groups expressed the HLA class II antigens rather more frequently than the corresponding CD4+ cells (88 and 68% versus 72 and 40%). Tfr-R expression was low on CD4+ and CD8+ SF T cells from both patient groups. SF T cells did not express CD30, and their expression of Act 1 did not differ from that of normal PB T cells. The RA ST findings were similar to those of RA SF. The overall expression of activation markers on PB T cells of patients was slightly higher than on those of normal controls, and the RA group was slightly higher than the non-RA group. The results show that intra-articular T cells in arthritis are activated and that CD4+ and CD8+ subsets differ in their expression of Tac antigen and HLA class II antigens. There were also similar patterns of activation markers on both CD4+ and CD8+ SF cells from RA and non-RA arthritis patients, suggesting that several types of arthritis display a similar immunopathogenesis in the joints.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2544985     DOI: 10.1111/j.1365-3083.1989.tb01167.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  8 in total

1.  Evidence for the presence of activated CD4 T cells with naive phenotype in the peripheral blood of patients with rheumatoid arthritis.

Authors:  D Maurer; T Felzmann; W Holter; P Petera; J Smolen; W Knapp
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

2.  Increased expression of CD40 ligand (CD154) on CD4+ T cells as a marker of disease activity in rheumatoid arthritis.

Authors:  B Berner; G Wolf; K M Hummel; G A Müller; M A Reuss-Borst
Journal:  Ann Rheum Dis       Date:  2000-03       Impact factor: 19.103

3.  Expression of cytolytic mediators by synovial fluid lymphocytes in rheumatoid arthritis.

Authors:  L H Young; S V Joag; P Y Lin; S F Luo; L M Zheng; C C Liu; J D Young
Journal:  Am J Pathol       Date:  1992-05       Impact factor: 4.307

4.  Spontaneous and in vitro activation of synovial fluid and peripheral blood lymphocytes in rheumatoid arthritis.

Authors:  Y T Konttinen; T Pettersson; P Kemppinen; C Friman
Journal:  Clin Rheumatol       Date:  1990-09       Impact factor: 2.980

5.  Synovial fibroblasts as target cells for staphylococcal enterotoxin-induced T-cell cytotoxicity.

Authors:  M Kraft; S Filsinger; K L Krämer; D Kabelitz; G M Hänsch; M Schoels
Journal:  Immunology       Date:  1998-01       Impact factor: 7.397

6.  Leflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of peripheral blood and synovial fluid mononuclear cells in rheumatoid arthritis.

Authors:  M Dimitrijevic; R R Bartlett
Journal:  Inflamm Res       Date:  1996-11       Impact factor: 4.575

7.  Cytolytic activity in T cell clones derived from human synovial rheumatoid membrane: inhibition by synovial fluid.

Authors:  A M Miltenburg; J M Van Laar; P De Kuiper; M R Daha; F C Breedveld
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

8.  Immunoregulatory role of interleukin 10 in rheumatoid arthritis.

Authors:  P D Katsikis; C Q Chu; F M Brennan; R N Maini; M Feldmann
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.